Indeed, it has previously been shown that elevated CaMKK2 expression is associated with a worse prognosis in patients with GBM using The Cancer Genome Atlas (TCGA) and the Chinese Glioma Genome Atlas (CGGA)29. This evidence concerns the gene CAMKK2 and central nervous system cancer.